Molecule/peptides
|
Glucose |
GOx-spherical AuNP (on a tapered fiber structure) |
LSPR (change in refractive index) |
322 μM |
0–10 mM |
— |
230
|
Glucose |
4-Cyanophenyl boronic acid (CPBA)-b-cyclodextrin (b-CD)-spherical AuNP |
Colorimetric (crosslinking) |
— |
1–20 mM |
Serum |
280
|
Glucose |
d-Glucose-spherical AuNP |
Colorimetric (AuNP growth) |
0.65 mM |
1.25–20 mM |
Human serum |
234
|
Glucose |
Spherical AuNP |
Colorimetric (AuNP growth) |
0.03 mM |
0.1–10 mM |
Serum |
281
|
Glucose |
Spherical AuNP |
Colorimetric (AuNP growth) |
0.081 mM |
0.3–5.0 mM |
Saliva |
282
|
Glucose |
Multibranched AuNP |
Colorimetric (etching) |
0.4 mg dL−1
|
— |
Saliva |
77
|
1.4 mg dL−1 (real samples) |
Glucose |
CTAB-Au nanorod |
Colorimetric (etching) |
LSPR: 0.1 μM |
0.3–1.0 μM |
Serum |
66
|
1.0–10 μM |
Naked eye: 3 μM |
3–30 μM |
Glucose |
Chitosan-spherical AuNP |
Indirect colorimetric (nanozyme) |
3 μM |
— |
60% serum |
81
|
Glucose |
Citrate-spherical AuNP |
FRET (donor: GOQD) |
0.65 μM |
2.5–75 μM |
Serum |
232
|
Glucose |
Citrate-spherical AuNP |
Colorimetric |
0.043 μM |
0–40 μM |
Urine |
283
|
Glucose (through H2O2) |
3-Mercaptophenylboronic acid (3-MPBA)-spherical AuNP |
SERS (change in ligand) |
H2O2: 70 nM |
70 nM to 150 μM |
Serum, urine |
231
|
Glucose: — |
0.5–5 mM |
Glycated hemoglobin |
Spherical AuNP |
Colorimetric (AuNP growth) |
0.124% of total hemoglobin |
— |
Whole blood |
236
|
Urea |
Citrate-spherical AuNP |
Indirect colorimetric (nanozyme) |
5 μM |
0.02–0.4 mM |
Human urine |
284
|
Dopamine |
Citrate-spherical AuNP |
Colorimetric (crosslinking) |
22 nM |
0.1–4 μM |
Human plasma, urine |
285
|
Dopamine |
Citrate-spherical AuNP |
Colorimetric (crosslinking) |
1.85 μM |
0–300 μM |
Urine |
225
|
FRET |
0.29 μM |
0–80 μM |
Glutathione |
Spherical AuNP (plant extract) |
Indirect colorimetric (nanozyme) |
0.013 μM |
1–40 μM |
Urine |
82
|
Glutathione |
Citrate-spherical AuNP |
FRET |
0.21 μM |
3.8–415.1 μM |
Serum |
97
|
|
Protein markers
|
Interleukin-6 |
Aptamer-spherical AuNP |
Colorimetric (crosslinking) |
1.95 μg mL−1
|
3.3–125 μg mL−1
|
— |
62
|
Hemoglobin |
2,6-Diaminopurine-spherical AuNP |
Indirect colorimetric (nanozyme) |
0.96 nM |
— |
Urine |
80
|
CA15-3 |
Antibody-Au nanorod |
Colorimetric (crosslinking) |
— |
— |
Human serum of breast cancer |
256
|
MUC4 |
(Antibody + SERS reporter)-spherical AuNP |
SERS |
— |
— |
— |
257
|
p53 mutant |
Aptamer-spherical AuNP |
Colorimetric (crosslinking) |
5 nM |
— |
— |
242
|
CEA |
Aptamer-spherical AuNP |
Colorimetric (crosslinking) |
3 ng mL−1
|
0.1–120 ng mL−1
|
Human serum |
260
|
Erα |
Aptamer-spherical AuNP |
Colorimetric (de-protection) |
2.4 ng mL−1
|
10 ng mL−1 to 5 μg mL−1
|
Cellular extract |
245
|
HER2 |
Aptamer-spherical AuNP |
Colorimetric (de-protection) |
10 ng mL−1
|
0–99 ng mL−1
|
10% serum |
244
|
AFP |
Antibody-spherical AuNP |
FRET |
400 pg mL−1
|
0.5–45 ng mL−1
|
Human serum |
246
|
AFP |
Spherical AuNP |
SERS (hot-spots with antibody-AgNPs) |
5 ng mL−1
|
0.05–10 μg mL−1
|
Fetal bovine serum |
258
|
AFP-L3 |
Antibody-spherical AuNP |
SERS (conformational change in linker) |
05 ng mL−1
|
0.5–1000 ng mL−1
|
Human serum |
122
|
PSA |
Aptamer-spherical AuNP |
Colorimetric (crosslinking) |
20 pg mL−1
|
0.1–100 ng mL−1
|
Human serum |
259
|
CA-125 |
DNA-spherical AuNP |
FRET |
1.5 fg mL−1
|
5 fg mL−1 to 50 ng mL−1
|
Human serum |
261
|
|
Acid nucleic markers
|
p53 |
Aptamer-spherical AuNP |
FRET (donor: FAM) |
1.6 pM |
5 pM–1 nM |
— |
241
|
BRCA1 mutation |
Aptamer-spherical AuNP on 2D material (GO, Bi2Se3) |
Indirect colorimetric (nanozyme) |
10−18 M |
10−18 to 10−12 M |
Extracted from patients' blood |
243
|
PCA3 |
Citrate-spherical AuNP |
PCR + colorimetric (anti-aggregation) |
31.25 ng |
— |
Urine |
247
|
3 sequences containing melanoma DNA mutations |
ssDNA-spherical AuNP |
SERS (+PCR) |
0.1% mutation (10 copies) |
— |
— |
250
|
PCA3 mimic DNA |
ssDNA-hollow AuNP |
SERS |
2.7 fM |
1 fM to 100 nM |
— |
251
|
microRNA |
Unfunctionalized spherical AuNP |
Colorimetric (de-protection) |
0.6 nM |
0.5 nM to 1 μM |
Total RNA extracted from cancer cells (MCF-7) and normal cells (HEK 293) |
252
|
FRET (donor: Aptamer-AgNC) |
0.4 pM |
1 pM–5 252μM |
|
Other markers
|
Tumor extracellular vesicles |
Aptamer-spherical AuNP |
SERS (creating hot-spots by organizing around an aptamer-agarose bead) |
2.44 pg μL−1
|
0.043–1240 ng μL−1
|
Human serum |
264
|
Exosome |
Antibody-spherical AuNP |
Colorimetric (plasmonic + immunoassay) |
8.54 × 105 exosomes per μL |
0–1.44 × 108 exosomes per μL |
— |
286
|
MCF-7 breast cancer cell |
150 nm spherical AuNP |
NIR SERS |
— |
— |
Human serum, plasma |
128
|
MCF-7 breast cancer cell |
Aptamer-Au nanorod |
Colorimetric (crosslinking) |
100 cells per mL |
102–105 cells per mL |
— |
265
|
MDA-MB-231 breast cancer cell |
Au nanostar |
SERS |
— |
10–500 cells per mL |
— |
287
|
Red blood cell |
2,6-Diaminopurine-spherical AuNP |
Indirect colorimetric (nanozyme) |
1.6 × 106 cells per L |
— |
Urine |
80
|
|
Infectious diseases
|
E. coli
|
Chimeric phage-spherical AuNP |
Colorimetric (crosslinking) |
∼102 CFU |
— |
— |
169
|
V. cholera
|
P. aeruginosa
|
Tuberculosis (DNA) |
Citrate-spherical AuNP |
Colorimetric (de-protection) |
1.95 × 10−2 ng mL−1
|
1.95 × 10−2 to 1.95 × 101 ng mL−1
|
Sample from 01 patient |
268
|
Tuberculosis (ManLAM lipoglycan) |
Antibody-spherical AuNP |
SERS |
0.8 ng mL−1 (46 pM) |
— |
Serum |
269
|
H3N2 influenza A virus |
Antibody-spherical AuNP |
Colorimetric (crosslinking) |
7.8 HA units |
10–80 HA units |
Clinical sample |
272
|
Influenza viruses |
Glycans-spherical AuNP |
Colorimetric (crosslinking) |
8 HA units |
— |
Clinical sample |
273
|
Tamiflu-resistant influenza virus |
Oseltamivir hexylthiol-spherical AuNP |
Colorimetric (crosslinking + lateral flow assay) |
1 × 104 PFU mL−1
|
— |
— |
271
|
H1N1 influenza A virus |
Positive charged spherical AuNP |
Indirect colorimetric (nanozyme) |
10.79 pg mL−1
|
10 pg mL−1 to 10 μg mL−1
|
Human serum |
270
|
H3N2 influenza A virus |
11.62 PFU mL−1
|
10–50 000 PFU mL−1
|
Newcastle disease virus (viral particle) |
Peptide–Cys-spherical AuNP |
Colorimetric (crosslinking) |
0.125 HA units |
— |
— |
61
|
DEVN WVN (viral particle) |
Citrate-spherical AuNP |
SERS (hot-spot: organization of AuNP on viral particles) |
10 PFU mL−1
|
— |
— |
116
|
MERS-CoV (upE gene) |
Citrate-spherical AuNP |
Colorimetric (crosslinking) |
1 pmol μL−1
|
— |
Real sample after PCR |
274
|
SARS-CoV-2 influenza B |
Sialic-spherical AuNP |
Colorimetric (crosslinking) |
— |
— |
Throat swab |
275
|
MERS-CoV (viral particle) |
SARS-CoV-2 (viral particle) |
(3 types of antibodies)-spherical AuNP |
Colorimetric (crosslinking) |
— |
— |
Throat swab |
224
|
SARS-CoV-2 (viral particle) |
ACE2 protein/mAbs-spherical AuNP |
Colorimetric (plasmonic + immunoassay) |
370 vp mL−1
|
0–107 vp mL−1
|
Pseudovirus |
276
|
SARS-CoV-2 (IgM antibody) |
(Anti-human IgM)-spherical AuNP |
Colorimetric (plasmonic + immunoassay) |
— |
— |
Serum |
86
|
SARS-CoV-2 (IgG antibody) |
Virus epitope-spherical AuNP |
Colorimetric (crosslinking) |
3.2 nM |
— |
Real plasma samples (including patients) |
277
|
SARS-CoV-2 Spike protein |
Aptamer-spherical AuNP |
Colorimetric (anti-aggregation) |
16 nM3540 |
— |
— |
279
|
Heat-inactivated virus |
Genome copies per μL |
SARS-CoV-2 (protease) |
Citrate-spherical AuNP |
Colorimetric (aggregation) |
10 pM |
0.01–0.5 nM |
— |
288
|